Published in Ann Rheum Dis on February 19, 2014
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun (2015) 0.86
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int (2016) 0.85
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis Rheumatol (2016) 0.78
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther (2016) 0.78
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken) (2016) 0.77
Making the next steps in psoriatic arthritis management: current status and future directions. Ther Adv Musculoskelet Dis (2015) 0.76
Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis (2015) 0.76
A novel biological target for the treatment of psoriatic arthritis. Immunotherapy (2014) 0.76
Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther (2016) 0.76
T Helper 17 Cells in Primary Sjögren's Syndrome. J Clin Med (2017) 0.76
Inflammatory osteolysis: a conspiracy against bone. J Clin Invest (2017) 0.76
Reflections on the Field of Human Genetics: A Call for Increased Disease Genetics Theory. Front Genet (2016) 0.75
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. J Clin Aesthet Dermatol (2014) 0.75
Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol (2014) 0.75
Advances in use of immunomodulatory agents--a rheumatology perspective. Nat Rev Gastroenterol Hepatol (2015) 0.75
Psoriatic arthritis is associated with bone loss of the metacarpals. Arthritis Res Ther (2016) 0.75
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol (2015) 0.75
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken) (2015) 0.75
Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol (2014) 0.75
Recent advances in understanding and managing psoriatic arthritis. F1000Res (2016) 0.75
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol (2017) 0.75
Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). Immunotargets Ther (2015) 0.75
Identifying a novel locus for psoriatic arthritis. Rheumatology (Oxford) (2015) 0.75
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. Rheumatol Ther (2015) 0.75
Biological agents in psoriatic arthritis. Wien Med Wochenschr (2014) 0.75
Th17 in Animal Models of Rheumatoid Arthritis. J Clin Med (2017) 0.75
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D (2017) 0.75
Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis (2005) 4.67
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med (2012) 4.38
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum (1992) 3.05
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum (2004) 2.62
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum (2007) 1.49
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest (2011) 1.38
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis (2002) 1.31
Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum (2005) 1.23
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord (2013) 1.22
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum (2007) 1.21
Psoriatic arthritis. J Am Acad Orthop Surg (2012) 1.06
Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. Rheumatology (Oxford) (2011) 0.98
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity (2008) 7.60
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nat Genet (2006) 3.54
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 3.42
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A (2011) 3.37
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol (2007) 2.82
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 2.78
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Interleukin-18. J Leukoc Biol (2003) 2.75
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 2.64
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol (2007) 2.43
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum (2004) 2.14
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol (2003) 1.93
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol (2010) 1.92
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol (2004) 1.88
Videos in clinical medicine. Ultrasound-guided internal jugular vein cannulation. N Engl J Med (2010) 1.88
Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum (2013) 1.84
Elevated CO2 induces physiological, biochemical and structural changes in leaves of Arabidopsis thaliana. New Phytol (2006) 1.80
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol (2012) 1.71
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis (2011) 1.63
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis (2010) 1.62
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther (2003) 1.61
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res (2007) 1.59
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Animal models of rheumatoid arthritis. Eur J Immunol (2009) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine (2002) 1.56
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.56
A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol (2004) 1.55
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats. J Clin Invest (2008) 1.53
Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion (2007) 1.51
New viral vaccines for dermatologic disease. J Am Acad Dermatol (2008) 1.50
Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin Vaccine Immunol (2007) 1.50
Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol (2010) 1.48
Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One (2013) 1.48
25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis (2012) 1.46
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol (2007) 1.44
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis (2009) 1.42
Community genetics. Its definition 2010. J Community Genet (2010) 1.42
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol (2005) 1.41
IL-33 exacerbates autoantibody-induced arthritis. J Immunol (2010) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Pseudocystic encapsulation: a late noninflammatory complication of hyaluronic acid filler injections. Dermatol Surg (2013) 1.39
CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum (2008) 1.39
Parvovirus B19-associated systemic lupus erythematosus: clinical mimicry or autoimmune induction? J Rheumatol (2010) 1.39
Acute generalized exanthematous pustulosis induced by terbinafine. Eur J Dermatol (2003) 1.38
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38